Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of NRX 195183 Therapy for Patients With Relapsed or Refractory Acute Promyelocytic Leukemia

NCT00675870 is registered in ClinicalTrials.gov with NuRx Pharmaceuticals, Inc. as lead sponsor.

NCT NCT00675870
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00675870 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of NRX 195183 Therapy for Patients With Relapsed or Refractory Acute Promyelocytic Leukemia
Lead sponsor
NuRx Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Unknown status
Start date
April 30, 2008
Completion date
Not reported
Enrollment
65 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute promyelocytic leukemia